Multinational pharmaceutical and diagnostics company OPKO Health has signed a definitive agreement to acquire Cytochroma.
Under the purchase, OPKO intends to include Cytochroma's Replidea and Alpharen, which are in Phase 3 clinical trials with kidney disease patients, into its product portfolio.
Vitamin D prohormone Replidea is designed to treat secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency, while Alpharen (Fermagate Tablets), a non-absorbed phosphate binder, is used to treat hyperphosphatemia in dialysis patients.
OPKO CEO and chairman Phillip Frost said as part of the acquisition, the company intends to market Replidea along with its proprietary point-of-care vitamin D diagnostic test which is currently in development.
"We envision these remarkable products as part of the foundation for a new and markedly improved standard of care for chronic kidney disease patients," Frost added.
